Complement in multiple sclerosis: its role in disease and potential as a biomarker.
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system with a poorly defined and complex immunopathogenesis. Although initiated by reactive T cells, persistent inflammation is evident throughout the disease course. A contribution from complement has long been suspected, based on the results of pathological and functional studies which have demonstrated complement activation products in MS brain and biological fluids. However, the extent and nature of complement activation and its contribution to disease phenotype and long-term outcome remain unclear. Furthermore, functional polymorphisms in components and regulators of the complement system which cause dysregulation, and are known to contribute to other autoimmune inflammatory disorders, have not been investigated to date in MS in any detail. In this paper we review evidence from pathological, animal model and human functional and genetic studies, implicating activation of complement in MS. We also evaluate the potential of complement components and regulators and their polymorphic variants as biomarkers of disease, and suggest appropriate directions for future research.
Ingram
G
G
Department of Neurosciences, Cardiff University, Heath Park, Cardiff, UK.
Hakobyan
S
S
Robertson
N P
NP
Morgan
B P
BP
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D003167:Complement Activation / Q000276:immunology; D003165:Complement System Proteins / Q000032:analysis / Q000276:immunology*; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology; D020022:Genetic Predisposition to Disease; D006801:Humans; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000235:genetics / Q000276:immunology*; D009471:Neuromyelitis Optica / Q000276:immunology
D015415:Biomarkers; D003165:Complement System Proteins